ES2587204T3 - Derivados de ácido biciclo (3.1.0) hexano-2,6-dicarboxílico como agonistas del receptor mGlu2 - Google Patents
Derivados de ácido biciclo (3.1.0) hexano-2,6-dicarboxílico como agonistas del receptor mGlu2 Download PDFInfo
- Publication number
- ES2587204T3 ES2587204T3 ES12729769.5T ES12729769T ES2587204T3 ES 2587204 T3 ES2587204 T3 ES 2587204T3 ES 12729769 T ES12729769 T ES 12729769T ES 2587204 T3 ES2587204 T3 ES 2587204T3
- Authority
- ES
- Spain
- Prior art keywords
- hydrogen
- optionally substituted
- fluorine atoms
- bicyclo
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11382208 | 2011-06-17 | ||
| EP11382208 | 2011-06-17 | ||
| US201161522791P | 2011-08-12 | 2011-08-12 | |
| US201161522791P | 2011-08-12 | ||
| PCT/US2012/041229 WO2012173850A1 (en) | 2011-06-17 | 2012-06-07 | Bicyclo (3.1.0) hexane- 2, 6 -dicarboxylic acid derivatives as mglu2 receptor agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2587204T3 true ES2587204T3 (es) | 2016-10-21 |
Family
ID=47357416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12729769.5T Active ES2587204T3 (es) | 2011-06-17 | 2012-06-07 | Derivados de ácido biciclo (3.1.0) hexano-2,6-dicarboxílico como agonistas del receptor mGlu2 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9296710B2 (enExample) |
| EP (1) | EP2721012B1 (enExample) |
| JP (1) | JP5945592B2 (enExample) |
| KR (1) | KR101598679B1 (enExample) |
| CN (1) | CN103596933B (enExample) |
| AU (1) | AU2012271024B2 (enExample) |
| BR (1) | BR112013031928B1 (enExample) |
| CA (1) | CA2836485C (enExample) |
| CY (1) | CY1117682T1 (enExample) |
| DK (1) | DK2721012T3 (enExample) |
| EA (1) | EA023553B1 (enExample) |
| ES (1) | ES2587204T3 (enExample) |
| HR (1) | HRP20160676T1 (enExample) |
| HU (1) | HUE030171T2 (enExample) |
| MX (1) | MX2013014802A (enExample) |
| PL (1) | PL2721012T3 (enExample) |
| PT (1) | PT2721012T (enExample) |
| RS (1) | RS54888B1 (enExample) |
| SI (1) | SI2721012T1 (enExample) |
| WO (1) | WO2012173850A1 (enExample) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993006127A1 (en) | 1991-09-17 | 1993-04-01 | Warner-Lambert Company | Novel amino acid prodrug renin inhibitors |
| US5576323A (en) | 1993-12-03 | 1996-11-19 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| US5849525A (en) | 1994-03-09 | 1998-12-15 | Brigham And Women's Hospital, Inc. | Compositions corresponding to a proton-coupled peptide transporter and methods of making and using same |
| US5688826A (en) | 1995-11-16 | 1997-11-18 | Eli Lilly And Company | Excitatory amino acid derivatives |
| CA2237910C (en) | 1995-11-16 | 2005-12-27 | Eli Lilly And Company | Excitatory amino acid derivatives |
| GB9605429D0 (en) * | 1995-11-16 | 1996-05-15 | Lilly Co Eli | Excitatory amino acid receptor antagonists |
| US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
| ZA983930B (en) | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
| WO1999038839A1 (en) | 1998-01-28 | 1999-08-05 | Taisho Pharmaceutical Co., Ltd. | Fluorine-containing amino acid derivatives |
| CA2341865C (en) | 1998-08-31 | 2006-01-17 | Taisho Pharmaceutical Co., Ltd. | 6-fluorobicyclo[3.1.0]hexane derivatives |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| KR20030017562A (ko) | 2000-06-28 | 2003-03-03 | 다이쇼 세이야꾸 가부시끼가이샤 | 신규 디카르복실산 유도체 |
| US7256217B2 (en) | 2001-01-11 | 2007-08-14 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| US7038077B2 (en) | 2001-01-11 | 2006-05-02 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| WO2002068380A1 (en) * | 2001-02-22 | 2002-09-06 | Eli Lilly And Company | Synthetic excitatory amino acids |
| US7067507B2 (en) | 2001-06-12 | 2006-06-27 | Pharmacia & Upjohn Company | Macrocycles useful in the treatment of Alzheimer's disease |
| MXPA04006322A (es) | 2001-12-27 | 2004-10-04 | Taisho Pharmaceutical Co Ltd | Derivados de 6-fluorobiciclo[3.1.0]hexano. |
| US20050192273A1 (en) | 2002-04-03 | 2005-09-01 | Johnson Bryan G. | Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
| EP1492595A1 (en) | 2002-04-03 | 2005-01-05 | Eli Lilly And Company | Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
| WO2003104217A2 (en) * | 2002-06-01 | 2003-12-18 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| CN100482680C (zh) * | 2002-06-11 | 2009-04-29 | 伊莱利利公司 | 兴奋性氨基酸前药 |
| WO2005000790A1 (ja) * | 2003-06-26 | 2005-01-06 | Taisho Pharmaceutical Co., Ltd. | ２－アミノビシクロ[３．１．０]ヘキサン－２，６－ジカルボン酸誘導体 |
| ES2355144T3 (es) * | 2003-06-26 | 2011-03-23 | Taisho Pharmaceutical Co., Ltd. | Derivado de éster 2-aminobiciclo 3.1.0 hexano-2,6-dicarboxílico. |
| US8735423B2 (en) * | 2009-11-18 | 2014-05-27 | Suven Life Sciences Limited | Bicyclic compounds as α4β2 nicotinic acetylcholine receptor ligands |
| AR079343A1 (es) * | 2009-12-21 | 2012-01-18 | Lilly Co Eli | Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico |
-
2012
- 2012-06-07 PL PL12729769T patent/PL2721012T3/pl unknown
- 2012-06-07 DK DK12729769.5T patent/DK2721012T3/en active
- 2012-06-07 US US14/123,768 patent/US9296710B2/en active Active
- 2012-06-07 WO PCT/US2012/041229 patent/WO2012173850A1/en not_active Ceased
- 2012-06-07 AU AU2012271024A patent/AU2012271024B2/en active Active
- 2012-06-07 JP JP2014515878A patent/JP5945592B2/ja active Active
- 2012-06-07 HR HRP20160676TT patent/HRP20160676T1/hr unknown
- 2012-06-07 KR KR1020137033028A patent/KR101598679B1/ko active Active
- 2012-06-07 CA CA2836485A patent/CA2836485C/en active Active
- 2012-06-07 MX MX2013014802A patent/MX2013014802A/es active IP Right Grant
- 2012-06-07 SI SI201230569A patent/SI2721012T1/sl unknown
- 2012-06-07 EP EP12729769.5A patent/EP2721012B1/en active Active
- 2012-06-07 BR BR112013031928-3A patent/BR112013031928B1/pt active IP Right Grant
- 2012-06-07 HU HUE12729769A patent/HUE030171T2/en unknown
- 2012-06-07 EA EA201391700A patent/EA023553B1/ru not_active IP Right Cessation
- 2012-06-07 RS RS20160491A patent/RS54888B1/sr unknown
- 2012-06-07 ES ES12729769.5T patent/ES2587204T3/es active Active
- 2012-06-07 PT PT127297695T patent/PT2721012T/pt unknown
- 2012-06-07 CN CN201280029080.2A patent/CN103596933B/zh active Active
-
2016
- 2016-06-24 CY CY20161100570T patent/CY1117682T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE030171T2 (en) | 2017-05-29 |
| SI2721012T1 (sl) | 2016-08-31 |
| JP5945592B2 (ja) | 2016-07-05 |
| MX2013014802A (es) | 2014-01-24 |
| BR112013031928A2 (pt) | 2016-12-13 |
| CA2836485A1 (en) | 2012-12-20 |
| KR101598679B1 (ko) | 2016-02-29 |
| KR20140009568A (ko) | 2014-01-22 |
| US20140113944A1 (en) | 2014-04-24 |
| CA2836485C (en) | 2016-12-13 |
| EA023553B1 (ru) | 2016-06-30 |
| RS54888B1 (sr) | 2016-10-31 |
| CY1117682T1 (el) | 2017-05-17 |
| CN103596933B (zh) | 2016-03-23 |
| EP2721012A1 (en) | 2014-04-23 |
| PL2721012T3 (pl) | 2017-05-31 |
| WO2012173850A1 (en) | 2012-12-20 |
| PT2721012T (pt) | 2016-07-27 |
| JP2014517035A (ja) | 2014-07-17 |
| DK2721012T3 (en) | 2016-08-15 |
| CN103596933A (zh) | 2014-02-19 |
| BR112013031928B1 (pt) | 2022-05-24 |
| EP2721012B1 (en) | 2016-05-25 |
| US9296710B2 (en) | 2016-03-29 |
| HRP20160676T1 (hr) | 2016-07-15 |
| AU2012271024B2 (en) | 2015-07-09 |
| AU2012271024A1 (en) | 2013-11-21 |
| EA201391700A1 (ru) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2855135T3 (es) | Amidas heterocíclicas como inhibidores de quinasa | |
| ES2425776T3 (es) | Derivados 1,2-disustituidos de 4-bencilamino-pirrolidina como inhibidores CETP útiles para el tratamiento de enfermedades tales como hiperlipidemia o arteriosclerosis | |
| ES2435651T3 (es) | Agonistas de MGLU2 | |
| ES2569712T3 (es) | Activadores de PKM2 bicíclicos | |
| CZ20012361A3 (cs) | Metoda pro léčení nemoci zprostředkované VLA-4, sloučenina a farmaceutický prostředek | |
| TW200902010A (en) | Anthranilamide inhibitors of aurora kinase | |
| ES2923002T3 (es) | Acido (2S,4R)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxailamino)-2-hidroximetil-2-metilpentanoico como inhibidor de la neprilisina | |
| ES2909709T3 (es) | Inhibidores del receptor 2 activado por proteasa | |
| ES2587204T3 (es) | Derivados de ácido biciclo (3.1.0) hexano-2,6-dicarboxílico como agonistas del receptor mGlu2 | |
| PT649843E (pt) | Derivado do tiazolino | |
| ES2380236T3 (es) | Compuesto de amida heterocíclica y uso del mismo | |
| ES2693545T3 (es) | Compuestos agonistas de GPR142 | |
| ES2324709T3 (es) | Agonistas de brs-3 no peptidicos. | |
| ES2318565T3 (es) | Inhibidores del receptor de la histamina h3, su preparacion y sus usos terapeuticos. | |
| ES2892276T3 (es) | Compuestos de benzamida ciclohexílica | |
| AU2013215396B2 (en) | MGLU 2/3 Agonists | |
| JP2014517035A5 (enExample) | ||
| PT2276759E (pt) | 3-indazolil-4-piridiltiazole | |
| BR112017017610B1 (pt) | Composto de fórmula (ii) ou um sal ou solvato farmaceuticamente a c e i t á v e i s d o m e s m o , u s o d o c o m p o s t o o u d o s a l o u s o l v a t o farmaceuticamente aceitáveis e composição farmacêutica |